title: Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH).
abstract: The coenzyme nicotinamide adenine dinucleotide (NADH) has been used as a novel medication in 161 Parkinson patients in an open label trial. In all but 18 patients (11.2%) an improvement in their disability was observed. 115 patients (71.4%) showed a very good (better than 30%) response, and 28 patients (17.4%) a moderate response up to 30%. The best results were obtained with a dose of 25 to 50 mg every second day by i.v. administration. Concomitantly with the improvement in disability, the urine HVA level increased significantly, indicating a stimulation of endogenous L-DOPA biosynthesis. 8 patients have been treated with nicotinamide adenine dinucleotidephosphate (NADPH), 5 of whom exhibited an improvement in their disability from 35 to 55%. The other 3 showed a moderate response of 20 to 25%. In all these patients an increase in the urine level of HVA was detected, reflecting elevated endogenous L-DOPA production.
authors.affiliation: Birkmayer Institute for Parkinson Therapy, Vienna, Austria.
authors.forename: G J
authors.initials: GJ
authors.lastname: Birkmayer
authors.forename: W
authors.initials: W
authors.lastname: Birkmayer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D006801:Humans; D007980:Levodopa / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009243:NAD / Q000627:therapeutic use*; D009249:NADP / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D009243:NAD; D007980:Levodopa; D009249:NADP